ecancer
ecancer is a UK charity which provides accessible, high-quality educational content, free to the global oncology community. Our mission is to raise the standards of care for cancer patients across the world through education.
Lung Cancers
ecancer
Anti-Tumor Activity of Tusamitamab Ravtansine Combined With Pembro +/- Chemo for Patients With Nonsquamous NSCLC
FEATURING
Luis Paz-Ares
- 107 views
- June 26, 2023
- 1
ecancer
EGFR Testing in NSCLC: Best Practice for Patients With Exon 20 Insertions
- 152 views
- April 13, 2022
ecancer
ESMO 2021 Updates on 1L Nivo+Ipi for Unresectable Malignant Pleural Mesothelioma: CheckMate 743 Results
FEATURING
Solange Peters
- 363 views
- October 22, 2021
- 1
ecancer
ESMO 2021 Highlights on Atezo vs. BSC After Adjuvant Chemo for Stage IB-IIIA NSCLC: IMpower010 Updates
FEATURING
Enriqueta Felip
- 18 views
- October 22, 2021
ecancer
ESMO 2021 Updates on Amivantamab +/- Lazertinib in Post-Osimertinib EGFRm NSCLC: CHRYSALIS Trial Results
FEATURING
Pascale Tomasino,
Catherine Shu
- 32 views
- October 22, 2021
ecancer
1L Nivo+Ipi+Chemo for Patients With Advanced NSCLC and Brain Mets: Results From CheckMate 9LA
FEATURING
David Carbone
- 656 views
- October 22, 2021
- 1
ecancer
ESMO 2020 Update on Stage 4 NSCLC: CPIs + Chemo, PD-L1, EGFR, and Other Targeted Therapies, Combination Therapies & Durvalumab OS
FEATURING
Luis Raez
- 139 views
- January 30, 2021
ecancer
2020 ESMO Update on ALK+ NSCLC: Lorlatinib vs. Crizotinib Efficacy Data
- 146 views
- January 5, 2021
ecancer
ESMO 2020 LungART Update on Completely Resected NSCLC: Is DFS Better With PORT vs. No PORT?
- 17 views
- January 5, 2021
ecancer
ESMO 2020 IMpower133 Update on ES-SCLC: Is 1L Chemo+/-Atezo Beneficial for PFS/OS?
- 83 views
- January 5, 2021
ecancer
ESMO 2020 Update on LS-SCLC: Ipi and Nivo vs. Observation After CRT
- 107 views
- January 5, 2021
- 1
ecancer
2020 ESMO LungART Update on Radiation Therapy in Completely Resected NSCLC: Is There a 3-year DFS Benefit With Post-Operative RT?
FEATURING
Cécile Le Péchoux
- 91 views
- November 13, 2020
ecancer
2020 ESMO Update on Advanced EGFR-Mutated NSCLC: How Effective Is EGFR-MET Amivantamab/Lazertinib Combination?
FEATURING
Alex Spira,
Joshua Sabari
- 116 views
- October 30, 2020
- 1
ecancer
2020 ESMO ADAURA CNS Analysis: What's Next for Adjuvant Osimertinib in Early Stage EGFR-Mutated NSCLC After Tumor Resection?
FEATURING
Masahiro Tsuboi
- 19 views
- October 30, 2020
ecancer
2020 ASCO Update on LS-SCLC: Is High-Dose Twice-Daily Thoracic RT Leading to Improved Survival?
FEATURING
Bjørn Henning Grønberg
- 59 views
- September 29, 2020
ecancer
2020 ASCO Update on Adjuvant Osimertinib in EGFR+ NSCLC: Are the Results of ADAURA Trial a Big Step Forward for NSCLC?
FEATURING
Luis Raez
- 562 views
- September 29, 2020
- 6
ecancer
2020 ASCO Update on Lung Cancer: 1L Atezo + Chemo, Ongoing Survival Benefit With Durvalumab in ES-SCLC, Nivolumab in Previously Treated mNSCLC
FEATURING
Luis Raez
- 439 views
- September 29, 2020
- 4
ecancer
2020 ASCO Update on Stage 4/Recurrent NSCLC: Should We Treat Patients With CPIs + 2 Cycles of Chemo vs. 4 Cycles of Chemo as 1L Option?
FEATURING
Martin Reck
- 335 views
- September 29, 2020
ecancer
The Role of Adjuvant Therapy in EGFRm Resectable NSCLC: Overview of ADAURA Data
FEATURING
Roy Herbst
- 285 views
- September 29, 2020
ecancer
Expert Discussion on EGFRm NSCLC: What Are the Latest Developments?
FEATURING
Alex Spira
- 409 views
- September 22, 2020
- 2